Physician profile
Eric Michael Feldman
NPI 1477509693
$9,667.15
in general payments reported to CMS, 2019-2025
24 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,695 · 2020: $1,237 · 2021: $696 · 2022: $575 · 2023: $1,907 · 2024: $752 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Travel and Lodging: $723 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.16 |
| Travel and Lodging | $722.89 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,917.38 | 2019-2023 | Senza |
| Abbott Laboratories | $2,618.81 | 2019-2025 | Proclaim, Prodigy, Octrode |
| Relievant Medsystems, INC. | $980.66 | 2019-2023 | Intracept |
| Boston Scientific Corporation | $540.55 | 2020-2025 | General - Therapies, Intracept Rf Probe, Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $354.74 | 2019-2020 | |
| Medtronic, INC. | $329.16 | 2021-2024 | Intellis Adaptivestim, Stealthstation S8 Platform |
| Collegium Pharmaceutical, INC. | $240.29 | 2020-2023 | Xtampza |
| Mml US, INC. | $227.53 | 2024-2025 | Reactiv8 |
| Nalu Medical, INC. | $214.62 | 2021-2024 | Nalu Neurostimulation System |
| Saluda Medical Americas, INC. | $201.13 | 2024-2025 | Evoke |
| Depuy Synthes Sales INC. | $174.04 | 2019 | |
| Spr Therapeutics, INC | $145.95 | 2024 | Sprint Pns System |
| Biodelivery Sciences International, INC. | $142.01 | 2019-2021 | |
| Biotronik Nro, INC. | $128.04 | 2024 | Prospera |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corelink, LLC | $100.00 | 2023 | |
| Janssen Biotech, INC. | $99.99 | 2024 | Darzalex |
| Daiichi Sankyo INC. | $38.43 | 2019 | |
| Amneal Pharmaceuticals LLC | $18.16 | 2023 | Rytary |
| Takeda Pharmaceuticals U.S.A., INC. | $15.80 | 2025 | Glassia |
| Biohaven Pharmaceuticals, INC. | $15.01 | 2021 | |
| Vertos Medical, INC. | $13.42 | 2019 | |
| Alfasigma USA, INC. | $13.34 | 2021 | |
| Pfizer INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.